Picture loading failed.

Anti-EGFR therapeutic antibody (Pre-made Matuzumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Matuzumab (formerly EMD 72000) is a humanized monoclonal antibody for the treatment of cancer. It binds to the epidermal growth factor receptor (EGFR) with high affinity. The mouse monoclonal antibody (mAb425) from which matuzumab was developed at the Wistar Institute in Philadelphia, Pennsylvania

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-337-1mg 1mg 3090
GMP-Bios-ab-337-10mg 10mg 21890
GMP-Bios-ab-337-100mg 100mg 148000
GMP-Bios-ab-337-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-EGFR therapeutic antibody (Pre-made Matuzumab biosimilar,Whole mAb)
INN Name Matuzumab
TargetEGFR
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCnd
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI Structure3c08:HL/5vr9:HL:AB
99% SI Structure5vsi:HL/3c09:HL:CB
95-98% SI StructureNone
Year Proposed2003
Year Recommended2003
CompaniesImClone Systems;Merck KGaA;Takeda
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedCervical cancer;Colorectal cancer;Gastric cancer;Head and neck cancer;Non-small cell lung cancer;Ovarian cancer
Development Techna